Neuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar® Platform
New automated features elevate the standard of care for NeuroStar® Advanced Therapy practices MALVERN, Pa.,…
Month: August 2023
Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression
Lead Asset KET01, an Oral Prolonged-Release Ketamine Formulation, Demonstrated Early Improvements in Depressive Severity Key…
Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression
Lead Asset KET01, an Oral Prolonged-Release Ketamine Formulation, Demonstrated Early Improvements in Depressive Severity Key…
Grace Breeding Provides Summary Update on Progress Related to its Leading Programs for the First Half of the Year
– Grace Breeding’s environmentally friendly proprietary NFT biofertilizer (Maoz™) receives first approval in Brazil and…
Grace Breeding Provides Summary Update on Progress Related to its Leading Programs for the First Half of the Year
– Grace Breeding’s environmentally friendly proprietary NFT biofertilizer (Maoz™) receives first approval in Brazil and…
IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology…
IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology…
Allogene Therapeutics Appoints Earl Douglas as General Counsel
Earl Douglas General Counsel, Allogene Therapeutics SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE)…
Allogene Therapeutics Appoints Earl Douglas as General Counsel
Earl Douglas General Counsel, Allogene Therapeutics SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE)…
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update
YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
SFA Therapeutics announces results for SFA-002 from Phase 1b Cohort 1 clinical trial for treatment of mild-to-moderate psoriasis
JENKINTOWN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) — SFA Therapeutics, a clinical-stage biotech using a first-in-class…
SFA Therapeutics announces results for SFA-002 from Phase 1b Cohort 1 clinical trial for treatment of mild-to-moderate psoriasis
JENKINTOWN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) — SFA Therapeutics, a clinical-stage biotech using a first-in-class…
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in…
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in…
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
Tel Aviv, Israel / Vancouver, Canada, Aug. 14, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc….
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
Tel Aviv, Israel / Vancouver, Canada, Aug. 14, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc….
Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd. MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) —…
Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
Patent developed in collaboration with Syngene International Ltd. MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) —…
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete…